Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy

Journal of Infectious Diseases

Volumn 204, Issue 8, 2011, Pages 1202-1210

  Satchell, Claudette S ^a   O'Halloran, Jane A ^b   Cotter, Aoife G ^b   Peace, Aaron J ^c   O'Connor, Eileen F ^b   Tedesco, Anthony F ^c   Feeney, Eoin R ^a   Lambert, John S ^b   Sheehan, Gerard J ^b   Kenny, Dermot ^c   Mallon, Patrick W G ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADENOSINE DIPHOSPHATE; ADRENALIN; ATAZANAVIR PLUS RITONAVIR; COLLAGEN; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; TENOFOVIR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADULT; COHORT STUDIES; COLLAGEN; CROSS-SECTIONAL STUDIES; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; EPINEPHRINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; STATISTICS, NONPARAMETRIC;

EID: 80052885199     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir509     Document Type: Article

References (38)

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
3. Rhew DC, Bernal M, Aguilar D, Iloeje U. GoetzMB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis 2003; 37:959-72.
4. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17:1179-93. (Pubitemid 36667761)
5. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35. (Pubitemid 46658704)
6. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26.
7. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-47. (Pubitemid 46292215)
8. The SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-24.
9. Durand M, Sheehy O, Baril J, et al. Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID). In: Program and abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Geneva, Switzerland: International Aids Society, 2009: TUPEB175.
10. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11:130-6.
11. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
12. Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. In: Program and abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Geneva, Switzerland: International AIDS Society, 2009: MOAB202.
13. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-38.
14. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001 [abstract 721]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal, Canada). Alexandria, VA: CROI, 2009.
15. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-8.
16. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-74. (Pubitemid 36019640)
17. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482-94.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95.
19. Harrison P, Keeling D. Platelet hyperactivity and risk of recurrent thrombosis. J Thromb Haemost 2006; 4:2544-6. (Pubitemid 44741544)
20. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK. Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49:657-66. (Pubitemid 46205039)
21. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the Prepare Post-Stenting Study. J Am Coll Cardiol 2005; 46:1820-6. (Pubitemid 41579802)
22. Satchell CS, Cotter AG, O'Connor EF, et al. Platelet function and HIV: a case-control study. AIDS 2010; 24:649-57.
23. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-54. (Pubitemid 46768608)
24. Joint Specialty Committee for Renal Association. Chronic kidney disease in adults: UK guidelines for identification, management and referral. London: Royal College of Physicians of London, 2006. http://www.renal.org/CKDguide/full/ UKCKDfull.pdf. Accessed 22 August 2011.
25. Moran N, Kiernan A, Dunne E, Edwards RJ, Shields DC. Kenny D. Monitoring modulators of platelet aggregation in a microtiter plate assay. Anal Biochem 2006; 357:77-84. (Pubitemid 44331163)
26. Peace AJ, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 6:1-8.
27. Najean Y, Ardaillou N, Dresch C. Platelet lifespan. Annu Rev Med 1969; 20:47-62.
28. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999; 1411:334-50. (Pubitemid 29221959)
29. Boerrigter G, Burnett JC Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 2007; 25:30-45. (Pubitemid 46625289)
30. Baum P, Kosikova G, Galkina S. Abacavir, a competitive inhibitor of soluble guanylyl cyclase, increases platelet reactivity [abstract 717]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: CROI, 2010.
31. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-7.
32. Olufadi R, Byrne CD. Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb 2006; 35:281-91. (Pubitemid 44155946)
33. Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101:264-9. (Pubitemid 30054153)
34. Humphries A, Amin J, Cooper D. Changes in cardiovascular biomarkers with abacavir: a randomized, 96-week trial [abstract 718]. In: Program and abtracts of the 17th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: CROI, 2010.
35. Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS 2008; 22:2540-3.
36. Palella FJ Jr., Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-65.
37. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med 2005; 165:2659-65. (Pubitemid 41785065)
38. Sabin C, Worm S, Weber R. Recent use of abacavir and didanosine, but not of thymidine analogues, is associated with risk of myocardial infarction [abstract 957c]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: CROI, 2008.